Organic Active Ingredients TRIZ Cases

Propylene glycol dissolves apixaban at high concentrations, reducing dose volume from 25 mL to under 10 mL while maintaining formulation stability.

Deuterated arachidonic acid stabilizes motor neurons against oxidative damage, reducing amyotrophic lateral sclerosis progression by at least 30%.

Radiolabelled ligands enable positron emission tomography imaging of TRP M8 receptors in the central nervous system.

Targeting conserved RdRP structures avoids drug resistance while maintaining low host cell toxicity.

Phase transfer catalysis achieves high regioselectivity for 2-substituted indazoles, eliminating complex chromatographic purification steps.

Guide RNA design differentiates mutant from wild-type RPS19 alleles, resolving allele specificity challenges while restoring functional protein expression.

Merging alpha-2-delta ligands and NSAIDs achieves synergistic inhibition of the micturition reflex, reducing side effects from high-dose monotherapy.

A sealed wipe impregnated with benzocaine delivers topical desensitization to the penis.

Topical acitretin gel employs co-solvents to increase solubility ten thousand times, reducing systemic side effects while maintaining therapeutic efficacy.

Merges thiazole-pyrimidine kinase inhibitors with checkpoint blockers to overcome tumor resistance and enhance survival rates.

Controlled-release anagrelide disrupts the platelet-cancer cell interaction loop, reducing metastasis while minimizing cardiovascular side effects.

A microneedle coating method uses freeze-dried reconstitution to achieve high viscosity with minimal solvent.

Co-administering KRAS and HDAC3 inhibitors overcomes acquired resistance in KRAS, LKB1 mutant lung cancer by restoring T-cell infiltration.

Pharmaceutical paste merges herbal extracts with chlorhexidine acetate to resolve low curative effect and recurrence risks in oral ulcer treatment.

Pyrazolo[1,5-a]pyrimidine compounds inhibit TrkA and TrkB kinases to treat pain and cancer without opioid side effects.

Antibody-mediated TRAIL delivery systems enhance stability and serum half-life for targeted cancer therapy.

Phytosterol esters form mixed micelles that solubilize lipophilic drugs, bypassing hepatic first-pass metabolism to improve systemic bioavailability.

Specific substituent groups on fused heterocyclic cores enhance selectivity over peak INa inhibition for cardiovascular disease treatment.

Inhibiting miR-144 and miR-451 activates the LKB1-AMPK-ULK1 pathway, resolving alpha-globin accumulation that overwhelms cellular detoxification.

Radial prism structures in agglomerated lactose carriers adsorb APIs to resolve cohesion forces and improve lung deposition accuracy.

Quaternary ammonium cation substituted heterocyclic compounds overcome Acinetobacter baumannii resistance through structural parameter changes.

4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid inhibits xanthine oxidase.

Antisense oligonucleotides target specific HD haplotypes to selectively reduce mutant HTT mRNA while preserving wild-type function.

Cationic guanidine polymers bind to HPV and HSV particles to prevent infection, overcoming limited vaccine coverage through universal viral inactivation.

Removing the pyridone structure eliminates phototoxicity and aggregation while maintaining anti-fibrotic efficacy across multiple organs.

Acidifying chitosan porous layers before embedding a fiber reinforcement member prevents matrix shrinkage and delamination during neutralization.

Nanostructured lipid carriers increase corneal residence time through mucoadhesion, reducing systemic toxicity from frequent dosing.

Macrocyclic compounds bind protein kinases to modulate enzymatic activity, resolving the contradiction between treatment efficacy and molecular specificity.

Novel 2-substituted aromatic ring-pyrimidine derivatives act as potent CHK1 kinase inhibitors to induce apoptosis in cancer cells.

Pre-formed human monoclonal antibodies bind influenza hemagglutinin to neutralize diverse viral subtypes, bypassing inefficient annual vaccine production.

A specific chemical compound suppresses retinal vascular permeability induced by vascular endothelial growth factor.

Thiolated hyaluronic acid crosslinks stabilize cationic liposomes, resolving the trade-off between structural integrity and payload release control.

Optimizing pH and ingredient concentrations creates a stable matrix that prevents active ingredient degradation during storage.

Biodegradable polymer microparticles encapsulate protease enzymes to resolve rapid degradation and frequent application requirements.

Combines BRAF, MEK, and EGFR inhibitors to reduce toxicity while improving survival in BRAF-mutant colorectal cancer.

A 4-hydroxyl group on the pyrimidine ring transforms synthetic intermediates into potent sGC stimulators, restoring NO pathway function.

Uses intermediary substances to lower kidney radiation dose, enabling higher tumor treatment efficacy without renal damage.

Modified linker regions in [18F]PSMA-1007 improve tumor permeability and visualization capability while resolving handling complexity issues.

Segmented tablet layers with fumaric acid salt and cellulose polymers prevent excessive initial drug release while sustaining therapeutic levels.

A nasal spray device delivers a corticosteroid plume with controlled droplet size distribution.

Acetylcysteine and sodium citrate stabilize pemetrexed solutions, preventing discoloration and precipitation during storage.

Combining mometasone furoate with olopatadine in a single formulation reduces allergic rhinitis onset to 15 minutes while maintaining treatment simplicity.

CAR-T cells targeting CD46 resolve specificity and effectiveness trade-offs.

Antisense oligonucleotides inhibit miR-27b activity to upregulate the Nrf2/ARE pathway, reducing oxidative stress and apoptosis in neurological disorders.

Nanoliposome aprepitant formulation eliminates toxic surfactants to improve solubility while preventing capillary blockage.

An electrospun fibrous matrix integrates drug-encapsulated microparticles into fibrils to overcome limited penetration in deep wounds.

Odiparcil replaces costly biotechnology treatments by enhancing N-acetylgalactosamine-4-sulfatase activity to reduce intracellular GAG accumulation.